Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00325065 · ClinicalTrials.gov registry record

Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders

A clinical trial of Mood Disorders, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
71
Enrollment target
1
Study location

NCT00325065 is a study of Mood Disorders that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 71 participants, below the 936-participant average among 39 other Mood Disorders trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00325065, a study of Mood Disorders, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
71 participants
Enrollment target
1
Study location

Study Summary

The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective processing of aversive signals. Moreover, we wish to examine whether increased vasopressin levels will increase, and increased oxytocin levels decrease, the neural response in the amygdala and other limbic structures to aversive stimuli. In addition, we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species....

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2006-05-05
Est. Completion 2010-04-16

What the Registry Record Tells You About NCT00325065

The ClinicalTrials.gov registry entry for NCT00325065 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 39 other Mood Disorders trials with a reported enrollment target (92% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mood Disorders appearing as the primary indexed condition, and to 0 interventions.

NCT00325065 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00325065 about?

NCT00325065 is a clinical study titled "Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders". The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective...

What is the current status of trial NCT00325065?

This trial is currently completed. The enrollment target is 71 participants. The study started on 2006-05-05. Estimated completion is 2010-04-16.

What conditions does trial NCT00325065 study?

This clinical trial studies the following conditions: Mood Disorders.

Who is sponsoring clinical trial NCT00325065?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00325065 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mood Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.